Ionis Pharmaceuticals Inc (IONS) Receives Average Rating of “Hold” from Brokerages

Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have been given a consensus recommendation of “Hold” by the seventeen ratings firms that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $49.90.

Several analysts have recently issued reports on IONS shares. Stifel Nicolaus restated a “hold” rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Friday, October 13th. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 target price on the stock in a research report on Friday, October 27th. Morgan Stanley upped their target price on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 8th. Finally, BMO Capital Markets upped their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 8th.

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) traded down $1.09 during midday trading on Friday, hitting $46.38. 441,569 shares of the stock traded hands, compared to its average volume of 972,698. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. The stock has a market cap of $6,272.22, a PE ratio of 309.49 and a beta of 2.53. Ionis Pharmaceuticals has a 52-week low of $37.26 and a 52-week high of $65.51.

In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 3,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $55.39, for a total value of $166,170.00. Following the transaction, the director now directly owns 7,127 shares in the company, valued at approximately $394,764.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the transaction, the chairman now owns 58,014 shares in the company, valued at $2,901,280.14. The disclosure for this sale can be found here. Insiders have sold a total of 133,885 shares of company stock worth $7,002,841 over the last quarter. 2.13% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of IONS. Ameriprise Financial Inc. grew its stake in Ionis Pharmaceuticals by 267.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 18,752 shares of the company’s stock worth $953,000 after acquiring an additional 13,647 shares in the last quarter. Northern Trust Corp grew its stake in Ionis Pharmaceuticals by 7.8% in the 2nd quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock worth $31,631,000 after acquiring an additional 44,750 shares in the last quarter. Ark Investment Management LLC grew its stake in Ionis Pharmaceuticals by 38.7% in the 2nd quarter. Ark Investment Management LLC now owns 176,991 shares of the company’s stock worth $9,004,000 after acquiring an additional 49,428 shares in the last quarter. Parametric Portfolio Associates LLC grew its stake in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 100,250 shares of the company’s stock worth $5,100,000 after acquiring an additional 387 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Ionis Pharmaceuticals by 15.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 196,812 shares of the company’s stock worth $10,014,000 after acquiring an additional 26,496 shares in the last quarter. Institutional investors and hedge funds own 91.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals Inc (IONS) Receives Average Rating of “Hold” from Brokerages” was published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/09/ionis-pharmaceuticals-inc-ions-receives-average-rating-of-hold-from-brokerages.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply